Unleashing the full potential of data to accelerate breakthroughs in cancer immunotherapy for patients

Jonathan Chainey, Global Head, Data Standards & Governance, PD Biometrics, Roche

LHC eSOURCE Symposium, 25 August 2020

Agenda

1. imCORE – Introduction
2. imCORE Funded Studies - Locations & Types
3. imCORE Sites & Data Capabilities - Survey Results
4. imCORE Data Repository & Data Flows
5. The Bigger Picture
6. Next Steps

imCORE* – Introduction

CLINICAL OPERATIONS ⟷ imCORE™ ⟷ SCIENTIFIC COLLABORATIONS

* **Im**munotherapy **C**enters **o**f **R**esearch **E**xcellence

- A **global network** of 27 leading cancer immunotherapy research sites
- Funded by Roche, co-led with Sage Bionetworks
- Goals:
  - Advance and accelerate cancer immunotherapy R&D
  - Harmonize clinical and biomarker data to support data sharing
- Currently 50+ investigator-initiated research studies

imCORE™

imCORE Funded Studies - Locations & Types





imCORE Sites & Data Capabilities - Survey Results



Results from 23 (out of 27) responses

imCORE™

imCORE Sites & Data Capabilities - Survey Results (cont.)

Is your site able to provide (send) your study data via FHIR services?

23 responses



imCORE Data Repository & Data Flows

CDISC selected as data model for imCORE data repository



The Bigger Picture



Next steps

- Build imCORE data repository using data model from Roche (CDISC + extensions)
- Partner with imCORE research sites to increase data capabilities esp. related to CDISC, HL7 FHIR
- Continue to seek alignment between CDISC, HL7
  - Vulcan - HL7 FHIR Accelerator
  - FDA Common Data Model Harmonization (using BRIDG)

imCORE™